URINARY CATHETERS MARKET ANALYSIS

Market Size and Trends

The global urinary catheters market is estimated to be valued at USD 5.83 Bn in 2024 and is expected to reach USD 8.69 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 5.9% from 2024 to 2031.

To learn more about this report, request a free sample copy

Rising geriatric population suffering from urinary incontinence issues and increasing prevalence of urinary disorders are expected to drive the demand for various urinary catheters. Additionally, growing number of surgical procedures and subsequent increase in the demand for post-operative urinary catheterization will further aid the market growth during the forecast years. Increased healthcare expenditure and availability of advanced catheter products will also support the overall adoption of urinary catheters globally.

Increasing Product Launches by Key Market Players

Increasing adoption of organic growth strategies, such as product launches, by key market players is expected to drive the global urinary catheters market growth over the forecast period. For instance, in December 2021, Otsuka Pharmaceutical Factory, Inc., a healthcare company, announced that it had launched Actreen, an intermittent urological catheter, which is used during self-catheterization of patients who have lost the urge to urinate or usually have difficulty urinating.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

Increasing initiatives taken by the market players in collaboration with government agencies by conducting awareness campaigns for the maintenance of women hygiene may act as a driver for the market growth over the forecast period. For instance, in May 2022, Santex Products (Pvt.) Ltd., a female hygiene product offering company, and the United Nations Children's Fund (UNICEF), in collaboration with the School Education & Literacy Department, Government of Sindh, Pakistan, announced the launch of NoChuttiPlus campaign to educate adolescent girls about Menstrual Health and Hygiene (MHH), as risks associated with poor hygiene can directly affect reproductive health and cause urinary tract infections.

To learn more about this report, request a free sample copy

Increasing number of product recalls by regulatory authorities, such as the U.S. Food and Drug Administration, is expected to hinder the market growth. For instance, in April 2020, the U.S. Food and Drug Administration recalled a class II device silicone foley catheter with a temperature sensor, which was manufactured by Covidien, a subsidiary of Medtronic, a medical device company. The device was recalled because the catheter failed to meet the established calibrated temperature sensing tolerance and correctly measure patient body temperatures that lead to an incorrect diagnosis and insufficient treatment.

Market Opportunities – Increasing Fundings from Organizations

Increasing adoption of inorganic growth strategies such as fundings is expected to offer lucrative growth opportunities in the market for the development of advanced urinary catheters. For instance, in August 2023, the Department of Biological Sciences at the University of Notre Dame, a private Catholic research university, Indiana, U.S. announced that it had been awarded funding from Open Philanthropy, a non-profit organization, for further development of a new type of urinary catheter that may reduce deaths from catheter-induced urinary tract infections (CAUTI).

To learn more about this report, request a free sample copy

The product type segment includes intermittent catheter, indwelling (foley) catheter, and external catheter. The intermittent catheter sub-segment is estimated to hold 54.3% of the market share in 2024 owing to its convenience and cost-effectiveness compared to other product types. Intermittent catheters allow flexible urination and do not require permanent insertion like an indwelling catheter. This makes intermittent catheters preferable for patients needing short-term catheterization. Their use is determined by the patient's urinary habits rather than being tied to a drainage bag continuously. This flexibility allows patients to lead relatively normal lifestyles. From a cost perspective as well, intermittent catheters have a lower unit cost compared to indwelling catheters which require longer-term use and constant maintenance. Their single-use nature also eliminates risks of complications from long-term indwelling. The convenience and affordability factors, along with their non-invasiveness, make intermittent catheters highly attractive for patients requiring temporary relief from urinary problems.

Insights, By Application: Increasing Prevalence of Urinary Incontinence

The application segment includes urinary incontinence, urinary retention, prostate gland surgeries, spinal cord injuries, and others. The urinary incontinence sub-segment is estimated to hold 39.1% of the market share in 2024 due to the growing burden of urinary incontinence. For instance, according to data published by American Urogynecologic Society, it was stated that the overall prevalence of urinary incontinence in adult U.S. women 20 years and older was 61.8%. Urinary incontinence significantly impacts daily activities and social engagement of patients. If left untreated, it can lead to social isolation, depression and mobility issues. Catheters help regain independence and restore confidence for incontinent patients. Among all applications, urinary incontinence has wide scope for catheter usage given its association with aging, childbirth, obesity, and neurological disorders. Managing incontinence effectively is critical to uphold patients' dignity and improve their participation in social roles.

Insights, By End User: Rising Focus on Clinical Excellence and Access Augments Hospitals Segment

The end user segment includes hospitals, specialty clinics, ambulatory surgical centers, and others. The hospitals sub-segment is estimated to hold 42.7% of the market share in 2024 owing to their prominence in clinical excellence and enhanced access for patients. Being the preferred healthcare facilities for critical illnesses and injuries, hospitals witness high throughput of urological cases needing catheterization. They are also increasingly focused on best practices to prevent healthcare-associated infections from improper catheter use. Furthermore, tertiary and quaternary hospital networks provide widespread coverage and role model clinical standards for other healthcare providers. This improves catheterization access for large patient volumes including those in remote areas.

Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global urinary catheters market and is estimated to hold 32.5% of the market share in 2024 owing to the presence of major industry players and growth of aging population in the region. The U.S. accounts for the largest share of the market due to a strong healthcare infrastructure and availability of advanced catheters. Additionally, favorable reimbursement policies have ensured the higher adoption of catheters driving the regional market growth.

Asia Pacific is poised to be the fastest growing market for urinary catheters over the forecast period. Countries such as China, India, Japan, and South Korea are expected to boost the regional market on account of rapid economic development and increasing healthcare investments. Rising medical tourism coupled with growing preference for low-cost devices available in the region is supporting the Asia Pacific market. Furthermore, the increasing incidence of urinary disorders among expanding aging population will accelerate the demand for urinary catheters in Asia Pacific.

Market Report Scope

Key Developments

• In June 2023, Convatec Inc., a medical device company, announced the launch of GentleCath Air, a new compact intermittent catheter for women, which is designed for ultimate discretion, convenience, and comfort
• In February, 2023, Coloplast Corp, a global healthcare company, announced that it had launched new intermittent catheter, Luja, which is designed to reduce the risk of urinary tract infections
• In July 2022, Otsuka Pharmaceutical Factory, Inc., a pharmaceutical company, announced the launch of OT-Balloon Catheter, an intermittent urological catheter. OT-Balloon Catheter is a reusable catheter for use during self-catheterization for people who have difficulty urinating spontaneously for various reasons. The catheter is temporarily implanted in the bladder by inflating the balloon at the tip of the catheter during the night or when going out.
• In March 2022, Sonoma Pharmaceuticals, Inc., a pharmaceutical company, announced that it had launched Microdox, a urinary tract infection catheter and bladder rinse in New Zealand, Australia, and South Africa. Microdox is a super-oxidized solution technology intended to treat and prevent infections in the urinary tract and bladder.
• In October 2021, Aurie, a mission-driven human centered medical device company, announced that the Aurie Reusable Intermittent Catheter System has received the Safer Technology designation from the U. S. Food and Drug Administration (FDA)

*Definition: A urinary catheter is a hollow, partially flexible tube that collects urine from the bladder and leads to a drainage bag. Urinary catheters come in many sizes and types. Catheters are made from rubber and non-rubber materials such as silicone. It is important to use the correct type of catheter and a non-rubber catheter is used if one is allergic to latex. A urinary catheter is used when an individual is having problems urinating naturally. It allows the individual or patient to urinate and drain while having an obstruction in the tube that carries urine out of the bladder (urethra).

Market Segmentation

•  Product Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Intermittent Catheter
    • Ported Peripheral Intravenous Catheters (PIVC)
    • Non-Ported Peripheral Intravenous Catheters (PIVC)
  • Indwelling (Foley) Catheter
  • External Catheter
•  Application Insights (Revenue, USD Bn, 2019 - 2031)
  • Urinary Incontinence
  • Urinary Retention
  • Prostate Gland Surgeries
  • Spinal Cord Injuries
  • Others
•  End User Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers
  • Others
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • B. Braun SE
  • Coloplast Corp
  • BD
  • Cathetrix
  • Hollister Incorporated
  • Boston Scientific Corporation
  • Medtronic
  • Bactiguard AB
  • Amecath
  • Urocare Products, Inc.
  • Rocamed
  • Cook
  • Ribbel International Limited
  • Sonoma Pharmaceuticals, Inc.
  • Affera, Inc.
  • Potrero Medical
  • Ingenion Medical
  • Otsuka Pharmaceutical Factory, Inc.